4.0 Editorial Material

When Context Is Hard to Come By: External Comparators and How to Use Them

Journal

THERAPEUTIC INNOVATION & REGULATORY SCIENCE
Volume 54, Issue 4, Pages 932-938

Publisher

SPRINGER HEIDELBERG
DOI: 10.1007/s43441-019-00108-z

Keywords

historical controls; synthetic controls; real-world evidence; real-world data; benchmark

Ask authors/readers for more resources

External comparators, also referred to as historical or synthetic controls, present transformational opportunities for broad context and insights alongside clinical research results. The recent confluence of access to quality real-world data (RWD), advanced epidemiologic methods, and legislative directives to regulators for expanded use of RWD is increasing interest in real-world external comparators, opening the door to achieve broader generalizability and learn more, faster. In this less standardized area of research, tailored scientific methodology must be applied for external comparators to accomplish clinical development objectives. Here, we describe methodological considerations for design and illustrate how RWD comparators have been used for regulatory and reimbursement decisions.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.0
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Editorial Material Public, Environmental & Occupational Health

Considerations in characterizing real-world data relevance and quality for regulatory purposes: A commentary

Cynthia J. Girman, Mary E. Ritchey, Wei Zhou, Nancy A. Dreyer

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2019)

Review Public, Environmental & Occupational Health

Trial designs using real-world data: The changing landscape of the regulatory approval process

Elodie Baumfeld Andre, Robert Reynolds, Patrick Caubel, Laurent Azoulay, Nancy A. Dreyer

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2020)

Article Medical Informatics

Masking in Pragmatic Trials: Who, What, and When to Blind

Jennifer B. Christian, Emily S. Brouwer, Cynthia J. Girman, Dimitri Bennett, Kourtney J. Davis, Nancy A. Dreyer

THERAPEUTIC INNOVATION & REGULATORY SCIENCE (2020)

Review Medical Informatics

Modernizing Regulatory Evidence with Trials and Real-World Studies

Nancy A. Dreyer, Marni Hall, Jennifer B. Christian

THERAPEUTIC INNOVATION & REGULATORY SCIENCE (2020)

Article Health Care Sciences & Services

Replication of randomized clinical trial results using real-world data: paving the way for effectiveness decisions

Kristin M. Sheffield, Nancy A. Dreyer, James F. Murray, Douglas E. Faries, Megan N. Klopchin

JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH (2020)

Article Economics

Use of External Comparators for Health Technology Assessment Submissions Based on Single-Arm Trials

Dony Patel, Fiona Grimson, Elena Mihaylova, Peter Wagner, Joss Warren, Anke van Engen, Joseph Kim

Summary: The study found that the number of SAT-based HTA submissions increased 13-fold between 2011 and 2019, with around 65% focused on oncology or hem-oncology. Of the 226 submissions, approximately 52% used some form of EC data, with an overall acceptance rate of 48% and 59% when including RWD EC data. The use of RWD ECs increased over time while prior trial ECs decreased, impacting acceptance rates.

VALUE IN HEALTH (2021)

Article Medicine, General & Internal

Identification of a Vulnerable Group for Post-Acute Sequelae of SARS-CoV-2 (PASC): People with Autoimmune Diseases Recover More Slowly from COVID-19

Nancy Dreyer, Natalia Petruski-Ivleva, Lisa Albert, Damir Mohamed, Emma Brinkley, Matthew Reynolds, Stephen Toovey

Summary: Individuals with underlying autoimmune conditions who use medications for these conditions are more likely to experience persistent COVID-19 symptoms, including shortness of breath and fatigue, after 30 days compared to those not using such medications. This suggests that early intervention may be necessary for this vulnerable population.

INTERNATIONAL JOURNAL OF GENERAL MEDICINE (2021)

Editorial Material Engineering, Biomedical

Resilient design: decentralized trials recovered faster from the impact of COVID-19 than traditional site-based designs

Jennifer Price, Noah Goodson, Edward J. Warren, Paul Wicks, John Reites

EXPERT REVIEW OF MEDICAL DEVICES (2021)

Article Health Care Sciences & Services

Evaluating real-world COVID-19 vaccine effectiveness using a test-negative case-control design

Matthew W. Reynolds, Alex Secora, Alice Joules, Lisa Albert, Emma Brinkley, Tom Kwon, Christina Mack, Stephen Toovey, Nancy A. Dreyer

Summary: This study assessed the real-world effectiveness of three COVID-19 vaccines and found all three to be highly effective.

JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH (2022)

Article Infectious Diseases

COVID-19 Vaccination Breakthrough Infections in a Real-World Setting: Using Community Reporters to Evaluate Vaccine Effectiveness

Matthew W. Reynolds, Yiqiong Xie, Kendall B. Knuth, Christina D. Mack, Emma Brinkley, Stephen Toovey, Nancy A. Dreyer

Summary: This study used adult community volunteers to obtain systematic information on vaccine effectiveness and breakthrough infections, showing a lower breakthrough infection rate in fully vaccinated individuals, with most cases being asymptomatic or having mild symptoms compared to unvaccinated cases.

INFECTION AND DRUG RESISTANCE (2022)

Article Medicine, General & Internal

Tactical Considerations for Designing Real-World Studies: Fit-for-Purpose Designs That Bridge Research and Practice

Nancy A. Dreyer, Christina Mack

Summary: Real-world evidence (RWE) is derived from real-world data (RWD) generated by clinicians and patients in everyday care settings. RWE is used to evaluate the real-world performance of medical interventions, services, and diagnostics, with a focus on diverse patient groups that may not be typically studied in traditional randomized clinical trials (RCT). This article provides guidance on study design and execution for clinicians interested in using RWE, including considerations about study participant representativeness, data transparency, and potential sources of bias. The authors also highlight the growing role of RWE in clinical, regulatory, and payer decision-making.

PRAGMATIC AND OBSERVATIONAL RESEARCH (2023)

Article Public, Environmental & Occupational Health

Self-reported symptoms from exposure to Covid-19 provide support to clinical diagnosis, triage and prognosis: An exploratory analysis

Nancy A. Dreyer, Matthew Reynolds, Christina DeFilippo Mack, Emma Brinkley, Natalia Petruski-Ivleva, Kalyani Hawaldar, Stephen Toovey, Jonathan Morris

TRAVEL MEDICINE AND INFECTIOUS DISEASE (2020)

Article Medical Informatics

Use of Big Data to Aid Patient Recruitment for Clinical Trials Involving Biosimilars and Rare Diseases

Raymond A. Hum, Jill Dawson, Karen Lipworth, Luis Rojas, Edward J. Warren, Charu Manaktala, Jonathan R. Huml

THERAPEUTIC INNOVATION & REGULATORY SCIENCE (2020)

No Data Available